All In Biotech

Drug Trial Radar · NCT07134335

UBT251 Injection Phase II Clinical Study (CKD)

A Phase II Clinical Study to Evaluate the Efficacy and Safety of UBT251 Injection in Obese/Overweight Chronic Kidney Disease (CKD) Population

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Sep 1, 2025

Primary completion

Jul 11, 2030

Study completion Jul 11, 2030

Sponsor

Sponsor type
Industry
First posted
Aug 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of UBT251 injection in obese/overweight chronic kidney disease (CKD) population

Conditions

  • Obesity &Amp; Overweight
  • Chronic Kidney Disease

Interventions

  • UBT251Drug

    Subcutaneous injection once weekly

  • UBT251Drug

    Subcutaneous injection once weekly

  • UBT251Drug

    Subcutaneous injection once weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. log-transformed urinary albumin:creatinine ratio(UACR)Time frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.